Latest Research Highlights
May 2024
-
In response to declining reimbursement and other market changes, community oncology practices (COPs) are strategically focusing on enhancing capabilities, expanding service offerings, and diversifying their payer base. HIRC's report, Community Oncology Practices: Market...
Apr 2024
-
Due to increasing cost management pressure from plan sponsors, PBMs continue to work to better manage the specialty drug trend. HIRC’s report, Pharmacy Benefit Managers: Specialty Medication Management and Contracting Trends, examines PBMs' involvement in specialty drug...
-
The specialty pharmaceuticals market environment continues to grow increasingly crowded with new approvals, expanded indications, and a growing list of biosimilar alternatives. HIRC’s report, Commercial Health Plans: Specialty Medication Management and Market Access,...
-
In light of increasing regulatory pressures shaping the Pharmacy Benefit Manager landscape, PBMs are strategically focusing on moderating drug spend and utilization while prioritizing patient affordability and access. HIRC's report, Pharmacy Benefit Managers: Market...
-
Pharmaceutical manufacturer account managers are critical to developing and maintaining favorable relationships with payer customers amid a complex managed care environment. HIRC's report, Best-in-Class Account Manager Insights, provides nominations of best-in-class account...
-
Integrated Delivery Networks (IDNs) continue to engage in a number of activities that can impact pharmaceutical market access. HIRC's report, Integrated Delivery Networks: Direct Contracting and Medication Management, reviews the landscape of direct contracting between IDNs...
Mar 2024
-
With ever-increasing payer cost controls and complex distribution logistics of novel therapies, Cancer Centers prioritize initiatives to enhance oncology pharmacy revenue, such as contracting and use of cost-effective medications. HIRC's report, Academic Institution &...
-
MCO account engagement supporting manufacturers' specialty product portfolios is critical as the market landscape grows more competitive across a range of therapeutic classes. HIRC’s report, Commercial Health Plans: Manufacturer Account Engagement and Contracting for...
-
Market access in the commercial health plan segment remains critical as plans seek alternative contracting approaches and opportunities to meaningfully collaborate with pharmaceutical manufacturers. HIRC's report, Commercial Health Plans: Contracting Landscape and...
-
Engagement with integrated delivery networks (IDNs) is an important component of manufacturers' market access strategies, especially as the reimbursement landscape shifts from volume to value. HIRC's report, Integrated Delivery Networks: Manufacturer Account Engagement and...
-
HIRC's Account Manager Performance report benchmarks 40+ pharmaceutical manufacturer account management teams based on managed care customer evaluations of skills and overall quality. The report provides insights into critical account manager success factors, as well as...
Feb 2024
-
Partnerships with pharmacy benefit managers (PBMs) are critical to maintaining favorable pharmaceutical product market access. HIRC's report, Pharmacy Benefit Managers: Contracting Landscape and Manufacturer Competitive Assessment, reviews pharmacy benefit manager...
-
Account managers play an important role in facilitating pharmaceutical manufacturers' relationships with Integrated Delivery Network (IDN) customers. HIRC's report, Integrated Delivery Networks: Evaluation of Pharmaceutical Manufacturer Account Managers, reviews IDNs'...
-
Cultivating collaborative and strategic relationships with key accounts is critical to ensuring access and maintaining partnerships across managed care markets. HIRC's Relationship Status and Customer Facing Access report benchmarks 40+ leading pharmaceutical manufacturers...
Jan 2024
-
Vertical integration between Plans, PBMs, GPOs, Specialty Pharmacies, and Providers continues to challenge pharmaceutical manufacturer access and partnership opportunities. An understanding of the access and partnership landscape for key accounts is critical for effective...
-
Pharmaceutical manufacturers continue to evolve managed markets staffing structures to meet customer needs as the market landscape changes due to continued consolidation and government policy changes. HIRC's report, Managed Markets Headcount and Organization Study, assists...
Nov 2023
-
The managed Medicaid segment continues to be impacted by policy changes and fluctuations in enrollment post-COVID. HIRC's report, Medicaid MCOs: Market Landscape Trends, Contracting Environment and Manufacturer Engagement, reviews the Medicaid MCO market landscape, the...
-
Pharmacy benefit managers (PBMs) continue to expand their service offerings in oncology drug management and contracting. HIRC's report, Pharmacy Benefit Managers: Oncology Medication Distribution, Formularies, and Contracting, examines PBMs' oncology medication management...
-
A number of innovative rare disease and gene therapy treatments have entered the market, requiring novel utilization management, financing, and contracting approaches. HIRC’s report, Rare Disease & Gene Therapy: Commercial Health Plan Management, Financing, and...
-
Medical/clinical science liaisons (MCSLs) play an important role in disseminating complex clinical and product information that assists Integrated Delivery Networks (IDNs) in making critical decisions that impact market access. HIRC's report, Integrated Delivery Networks:...
Oct 2023
-
Specialty pharmacies are developing robust and unique capabilities to support the upcoming pipeline of rare disease & gene therapies, and can serve as strong partners in patient access and adherence. HIRC’s report, Rare Disease & Gene Therapy: Specialty Pharmacy...
-
Looking ahead of the implementation of the Inflation Reduction Act (IRA), Medicare Advantage plans are working towards more aggressive contracts as well as tighter cost and utilization management of oncology medications. HIRC's report, Medicare Advantage Plans: Oncology...
-
Relevant and useful manufacturer-sponsored support programs and resources can help drive collaborative and strategic partnerships with Integrated Delivery Network (IDN) customers. HIRC's report, Integrated Delivery Networks: Evaluation of Pharmaceutical Manufacturer...
Sep 2023
-
Looking ahead to the full implementation of the Inflation Reduction Act, Medicare Advantage (MA) plans are working to tighten formulary & utilization management and enhance contracting with manufacturers for specialty medications. HIRC’s report, Medicare Advantage Plans...
-
There are many opportunities for manufacturers to align resources and offerings to the quality and population health objectives of Integrated Delivery Network (IDN) customers. HIRC's report, Integrated Delivery Networks: Quality and Population Health Management Goals and...
Aug 2023
-
As the Inflation Reduction Act (IRA) poses new challenges, Medicare Advantage plans seek aggressive contracting opportunities as well as increased UM and formulary management to control costs. HIRC's report, Medicare Advantage Plans: Market Landscape Trends, Contracting...
-
Biosimilars have changed the competitive environment across key therapeutic areas such as inflammation & immunology, cancer supportive therapies, and oncology. HIRC's report, Biosimilars: Adoption & Contracting Trends, 2023, examines payer and provider adoption and...
Jul 2023
-
Commercial health plans are working to manage the cost of oncology medications more aggressively as utilization of oncology drugs and the overall cost of cancer care increases. HIRC's report, Commercial Health Plans: Oncology Medication Management and Market Access, reviews...
-
Pharmaceutical manufacturer contracting is a key element of account engagement to enhance and/or maintain market access; however, the contracting landscape can vary greatly upon on many idiosyncrasies within each therapeutic area. HIRC's report, The Contracting Environment...
Jun 2023
-
As commercial health plans become more aggressive in targeting oncology in cost saving initiatives, manufacturer engagement and contracting where appropriate remains imperative to continue to ensure market access and remain competitive. HIRC's report, Commercial Health...
-
Payers continue to seek manufacturer-sponsored programs and support resources to help ease the cost burden of medications, drive value, and improve overall outcomes for members. HIRC's report, Managed Markets Marketing Programs and Account Support Offerings, provides an in-...
-
While very few vertically-integrated firms control the majority of specialty pharmacy market share, the market landscape is nothing short of dynamic as health systems enhance access and regulatory activity continues to emerge and develop. HIRC’s report, Specialty Pharmacy...
May 2023
-
Specialty pharmacy provider (SPP) partnerships can effectively shape the brand experience and enhance patient and market access. HIRC’s report, Specialty Pharmacy Providers: Manufacturer Engagement and Contracting Trends, examines SPPs' evaluation of manufacturers and...
-
Integrated Delivery Networks (IDNs) report a number of market challenges impacting their businesses in 2023; however, this comes alongside some positive signals of pandemic recovery. HIRC's report, Integrated Delivery Networks: Market Landscape and Strategic Imperatives,...
-
Medical/clinical science liaisons represent an essential component of the manufacturer-payor relationship by acting as field-based clinical experts responsible for providing objective scientific education and support to address customers informational needs. HIRC's report,...
-
HIRC's Medical/Clinical Science Liaison Performance report benchmarks 40+ leading pharmaceutical MCSL teams based on managed care customer evaluations of MCSL skills and overall quality. The report provides insights into critical MCSL success factors, as well as customer...
